"PPA-Free" Ads Spring Up In Wake Of FDA Consumer Warning
This article was originally published in The Tan Sheet
Executive Summary
FDA's consumer advisory on phenylpropanolamine has spawned a plethora of ads and public relations campaigns by companies highlighting the safety of their "PPA-free" remedies as the cold and flu season gets underway.
You may also be interested in...
PPA Still Available In U.K., Under Review In Canada
Federal regulatory agencies in Canada and the U.K. have not followed FDA's lead in asking manufacturers to voluntarily halt distribution of all OTC products containing phenylpropanolamine.
Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC